AstraZeneca
AZN
787 hedge funds and large institutions have $19.7B invested in AstraZeneca in 2020 Q4 according to their latest regulatory filings, with 150 funds opening new positions, 273 increasing their positions, 226 reducing their positions, and 75 closing their positions.
200% more funds holding in top 10
Funds holding in top 10: 6 → 18 (+12)
100% more first-time investments, than exits
New positions opened: 150 | Existing positions closed: 75
21% more repeat investments, than reductions
Existing positions increased: 273 | Existing positions reduced: 226
9% more funds holding
Funds holding: 723 → 787 (+64)
9% more call options, than puts
Call options by funds: $458M | Put options by funds: $421M
0.52% less ownership
Funds ownership: 15.52% → 15% (-0.52%)
12% less capital invested
Capital invested by funds: $22.4B → $19.7B (-$2.64B)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$271M |
| 2 |
GQG Partners
Ft. Lauderdale,
Florida
|
+$244M |
| 3 |
D.E. Shaw & Co
New York
|
+$224M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
+$199M |
| 5 |
Voloridge Investment Management
Jupiter,
Florida
|
+$163M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jennison Associates
New York
|
-$1.12B |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$1B |
| 3 |
Dodge & Cox
San Francisco,
California
|
-$609M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
-$186M |
| 5 |
Capital International Investors
Los Angeles,
California
|
-$173M |
AZN Hedge Fund Activity: Q4 2020 in Review
787 of the 5,676 institutional investors tracked by Wall St. Rank reported a position in AstraZeneca (AZN) for Q4 2020, worth a combined $19.7B — down 12% from $22.4B a quarter earlier.
Buyers outnumbered sellers: 150 funds opened new AZN positions and 75 closed out — a net gain of 75 holders — while 273 added to existing stakes and 226 trimmed.
The largest buyer was BlackRock, adding an estimated $271M. The largest seller was Jennison Associates, cutting an estimated $1.12B.
- 787 institutional investors held AstraZeneca (AZN) as of Q4 2020, up from 723 in Q3 2020.
- Funds reported $19.7B of AstraZeneca stock for Q4 2020, down 12% quarter-over-quarter.
- 150 funds opened new AstraZeneca positions in Q4 2020 and 75 closed out, a net change of +75 holders.
- The largest AstraZeneca buyer in Q4 2020 was BlackRock, an estimated $271M added.
- The largest AstraZeneca seller in Q4 2020 was Jennison Associates, an estimated $1.12B sold.
Based on aggregated 13F filings for Q4 2020.